Thyme Care Raises $125 Million in Series E Funding
Thyme Care, a healthcare company focused on improving the cancer journey through expert oncology navigation and care team partnerships, has successfully raised $125 million in its Series E funding round. This latest round was led by Morgan Health, with significant participation from Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures, and a16z.
Company Overview
Based in Nashville, Tennessee, Thyme Care is dedicated to enhancing the cancer care experience by providing patients with improved access to oncology services, better outcomes, and reduced costs. The company collaborates with a diverse team of oncology experts to guide patients through their treatment journey.
Leadership
Thyme Care was co-founded by Bobby Green, who serves as the President and Chief Medical Officer, and Robin Shah, the Chief Executive Officer. Together, they have been instrumental in steering the company towards its mission of revolutionizing cancer care.
Strategic Use of Funds
While specific plans for the newly acquired funds have not been disclosed, the investment is expected to further Thyme Care's efforts in expanding its oncology services and enhancing its technological capabilities to better serve patients.
Investor Confidence
The participation of prominent investors such as Morgan Health, Humana, and CVS Health Ventures underscores the growing interest and confidence in Thyme Care's innovative approach to cancer care. This funding round marks a significant milestone in the company's journey, enabling it to continue its mission of transforming the oncology landscape.